While there are more than six million people worldwide with sickle cell, most of whom living in sub-Saharan Africa, the initial launches are expected to focus on tens of thousands of patients in the United States and Europe.Record-setting price tags for gene therapies have largely escaped the criticism that has followed other industry pricing decisions....